News Releases

This section contains information and press releases about Boston Scientific. Press releases are listed in chronological order and archived by year. Information should be considered accurate as of the date prepared. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Boston Scientific is not obligated to update the press releases and information contained in this section of the website.

Click here to access archived Guidant press releases.

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005 / 2004

2008 Archives

	Dec 18, 2008 Boston Scientific Initiates Carotid Stent Clinical Study Boston Scientific Corporation today announced enrollment of the first patient... More
	Dec 15, 2008 FDA Approves Boston Scientific's Express® SD Renal Stent System First low-profile, pre-mounted stent approved specifically for use in renal arteries Boston Scientific Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved the Express® SD Renal Monorail®... More
	Nov 24, 2008 Boston Scientific to Participate in Piper Jaffray Health Care Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Piper Jaffray Health Care Conference, which is being held December 2 -... More
	Nov 10, 2008 FDA Approves Boston Scientific's Apex™ PTCA Dilatation Catheter New design provides more options for treating patients with complex lesions Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the U.S. Food and Drug Administration to market its... More
	Oct 29, 2008 Boston Scientific Welcomes Passage of Federal Pain Care Legislation to Benefit Military Members and Veterans Boston Scientific Corporation (NYSE: BSX) today welcomed passage of legislation to help active members of the U.S. armed forces and service... More
	Oct 27, 2008 UK's NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain Confirms clinical value and cost-effectiveness of spinal cord stimulation Boston Scientific Corporation (NYSE: BSX) today welcomed an announcement by the U.K.'s National Institute for Health and Clinical Excellence (NICE)... More
	Oct 23, 2008 FDA Approves Boston Scientific's Carotid Artery Stent Leading carotid stent in Europe and other international markets now available in the United States Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved its Carotid WALLSTENT®... More
	Oct 21, 2008 Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2008, as well as guidance for... More
	Oct 15, 2008 HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS® Drug-Eluting Stents in Heart Attack Patients Landmark trial provides new insight for physicians Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of the HORIZONS AMI trial. The HORIZONS AMI... More
	Oct 15, 2008 TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated with Second-Generation TAXUS® Liberte® Stent Boston Scientific Corporation (NYSE: BSX) today announced positive one-year results from the Intercontinental and European launch... More
	Oct 14, 2008 SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS® Express2™ Stents and Bypass Surgery New SYNTAX Score shows similar safety and efficacy outcomes for two thirds of study's patients Boston Scientific Corporation (NYSE: BSX) today announced 12-month left main and three-vessel disease subset data from its landmark... More
	Oct 14, 2008 Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet Company moves up Q3 earnings release date Boston Scientific Corporation (NYSE: BSX) today provided the following comments reinforcing the strength of its balance sheet: The volatility of... More
	Oct 14, 2008 Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter TAXUS® Atom™ in more than 500 accounts Company opening new PROMUS™ accounts Boston Scientific Corporation (NYSE: BSX) today announced estimated U.S. market shares for September for its two drug-eluting stents (DES), based... More
	Oct 13, 2008 GE Healthcare and Boston Scientific Collaborate on Cardiovascular Imaging Joint efforts will focus on intravascular ultrasound (IVUS) GE Healthcare (NYSE: GE) and intravascular ultrasound (IVUS) market leader Boston Scientific Corporation (NYSE: BSX) today... More
	Oct 13, 2008 Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders Thursday and Friday of last week saw continued heavy trading in Boston Scientific's (NYSE: BSX) stock. As anticipated in the Company's October 9th... More
	Oct 12, 2008 TAXUS® Express® Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of nearly 7,500 patients from its TAXUS ARRIVE 1... More
	Oct 12, 2008 Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent New coronary stent features thin struts designed for more uniform drug delivery Boston Scientific Corporation (NYSE: BSX) today announced comprehensive data from the TAXUS ATLAS clinical program, a series of... More
	Oct 10, 2008 Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS® Liberte® Drug-Eluting Stent Boston Scientific Corporation (NYSE: BSX) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its... More
	Oct 10, 2008 Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS® Coronary Stent Systems at TCT 2008 Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Cardiovascular... More
	Oct 9, 2008 Boston Scientific Comments on Involuntary Selling of Its Stock by Co-Founders Yesterday saw heavy trading in Boston Scientific's (NYSE: BSX) stock, with approximately 38 million shares traded. This trading included involuntary... More
	Oct 8, 2008 Boston Scientific Announces Third Quarter Adjustments Boston Scientific (NYSE: BSX) announced today it expects to record the following adjustments to its third quarter results, which it plans to report... More
	Oct 8, 2008 Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent PERSEUS clinical program to evaluate TAXUS® Element™ Platinum Chromium Stent Boston Scientific Corporation (NYSE: BSX) today announced that it has completed enrollment in the PERSEUS trial, designed to evaluate the Company's... More
	Oct 1, 2008 Boston Scientific Announces Court Decision Boston Scientific Corporation (NYSE: BSX) announced today that the United States District Court in Delaware has entered judgment against the Company... More
	Sep 25, 2008 Boston Scientific Announces FDA Approval of TAXUS® Express2™ Atom™ Stent System, First Drug-Eluting Stent For Small Vessels Company also announces FDA approval of TAXUS® Express2™ Stent System for treatment of in-stent restenosis Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market... More
	Sep 19, 2008 Boston Scientific to Participate in UBS Global Life Sciences Conference Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the UBS Global Life Sciences Conference, which is being held September 22... More
1-25 26-50 51-75 76-92